



Pfizer Inc.
275 North Field Drive
Lake Forest, IL 60045

June 22, 2017

Notification on Pfizer Injectables Supply Recovery Update

Dear Valued Customer,

We are writing to share recent developments in our supply recovery efforts, and to provide an updated list of the anticipated recovery timeframes for select products. Pfizer Injectables has a dedicated team focused on the execution of our supply recovery plan, and are providing the following updates below. Please feel free to share this letter with your clinicians as well.

- Expediting supply to the market by prioritizing shipments to the wholesale channel
- Realigned distribution processes to better serve customer needs
- Received FDA approval/endorsement for extended use dating for products with short supply – please visit FDA's website for more information: <https://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm563360.htm>
- Shared ongoing communications regarding supply recovery including, *Restoring Your Confidence Customer WebEx Series*, where senior leadership answered questions live
- Decided not to implement July 1 price increases on Pfizer Injectables products

We have included an updated list that details the anticipated recovery timeframe for select products. However, this information is subject to change and therefore, we recommend that you leverage our availability report on our website at https://www.pfizerinjectables.com/Injectables_Availability_Report to receive the most up-to-date information on Pfizer Injectables product availability. You can also contact us via our Supply Continuity Team between 7:00am – 6pm CT to discuss any product availability questions that you may have. They can be reached at 1-844-646-4398 (For customers, select option 1, then select option 3) or at PISupplyContinuity@Pfizer.com.

We value our relationship with you and remain committed to restoring your confidence in us as a provider of high-quality sterile injectable drugs. We will continue to communicate with you on important updates to help you manage your drug needs for patient care. We are available to speak with you to discuss this in more detail, and answer any questions that you may have. Please email us at PfizerInjectables@Pfizer.com and we will respond to you as quickly as possible.

Kind regards,

Ellen Wetterling
US Portfolio Lead

Drug Delivery Systems, Brand Marketing,
Anti-Infectives, Opioids & Oncology

Dave Engels
US Portfolio Lead

Surgical & Specialty Brand Marketing,
Anesthesia & Injectables

| NDC Number | Product Description | Is Inventory Depleted? | Next delivery (will not meet full market demand) | Full recovery expected with consistent supply |
|---------------------------|--|------------------------|--|---|
| 60793-700-10 | Bicillin™ L-A (penicillin G benzathine injectable suspension) Pediatric 600,000 Units/mL PFS | NO - Allocating | August | October - December |
| 60793-701-10 | Bicillin™ L-A (penicillin G benzathine injectable suspension) 1.2 million units/2 mL (600,000 units/mL) PFS | NO - Allocating | July | October - December |
| 60793-702-10 | Bicillin™ L-A (penicillin G benzathine injectable suspension) 2.4 million units/4 mL (600,000 units/mL) PFS | NO - Allocating | September | October - December |
| 0409-1283-05 | Hydromorphone Hydrochloride Injection, USP, CII 0.5 mg/0.5 mL iSecure™ Luer Lock Glass Syringe (no needle) | YES | Late June | September |
| 0409-2267-20 | Labetalol Hydrochloride Injection, USP 100 mg/20 mL (5 mg/mL) Multiple Dose Glass Fliptop Vial | YES | Late June | Mid August |
| 0409-2339-34 | Labetalol Hydrochloride Injection, USP 20 mg/4 mL (5 mg/mL) CARPUJECT™ Luer Lock Glass Syringe (no needle) | YES | Late June | September |
| 0409-2267-54 | Labetalol Hydrochloride Injection, USP 200 mg/40 mL (5 mg/mL) Multiple Dose Glass Fliptop Vial | YES | Late June | Mid August |
| 61703-350-38 | Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL) Glass Fliptop Vial | NO - Allocating | Mid July | July - September |
| 61703-408-41 | Methotrexate Injection, USP 1 g/40 mL (25 mg/mL) Single Dose Glass Fliptop Vial | NO - Allocating | Early August | July - September |
| 0409-7295-01 | Potassium Phosphates Injection, USP, 45 mM P/15 mL (3 mM P/mL) Single Dose Glass Fliptop Vial | YES | Late July | July - September |
| 0409-7391-72 | Sodium Phosphates Injection, USP 45 mEq/15 mL (3 mEq/mL) Single Dose Plastic Fliptop Vial | NO - Allocating | Mid July | April - June 2018 |
| 0409-3299-05 | Sodium Acetate Injection, USP 100 mEq/50 mL (2 mEq/mL) Pharmacy Bulk Package Glass Fliptop Vial | YES | Late July | December |
| 0409-3299-06 | Sodium Acetate Injection, USP 200 mEq/100 mL (2 mEq/mL) Pharmacy Bulk Package Glass Fliptop Vial | YES | Late July | December |
| 0409-7299-73 | Sodium Acetate Injection, USP 40 mEq/20 mL (2 mEq/mL) Single Dose Plastic Fliptop Vial | NO - Allocating | August | Early December |
| 0409-6625-02 | Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL) Single Dose Glass Fliptop Vial (8.4% concentration) | YES | Under review | Under review |
| 0013-8717-62 | Zinecard™ (dexrazoxane for injection) 250 mg Single Dose Vial | YES | October - December | October - December |
| 0013-8727-89 | Zinecard™ (dexrazoxane for injection) 500 mg Single Dose Vial | YES | July - September 2018 | July - September 2018 |
| Emergency Syringes | | | | |
| 0409-4911-34 | Atropine Sulfate Injection, USP (Adult) 1 mg/10 mL (0.1 mg/mL) LifeShield™ ABBOJECT™ Glass Syringe (20 G x 1 1/2") | YES | June | October |
| 0409-4910-34 | Atropine Sulfate Injection, USP (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield™ ABBOJECT™ Glass Syringe (20 G x 1 1/2") | YES | Early August | September |
| 0409-1630-10 | Atropine Sulfate Injection, USP (Adult) 1 mg/10 mL (0.1 mg/mL) ANSYR™ Plastic Syringe | YES | June | September |
| 0409-9630-05 | Atropine Sulfate Injection, USP (Pediatric) 0.25 mg/5 mL (0.05 mg/mL) ANSYR™ Plastic Syringe | YES | Late June | Late June |
| 0409-4928-34 | Calcium Chloride Injection, USP 1 g/10 mL (100 mg/mL) LifeShield™ ABBOJECT™ Glass Syringe (20 G x 1 1/2") | YES | Late June | October |
| 0409-1631-10 | Calcium Chloride Injection, USP 1 g/10 mL (100 mg/mL) ANSYR™ Plastic Syringe | NO - Allocating | Mid August | October |
| 0409-1775-10 | 25% Dextrose Injection, USP (For Infant Use) 2.5 g/10 mL (250 mg/mL) ANSYR™ Plastic Syringe | YES | August | August |
| 0409-7517-16 | 50% Dextrose Injection, USP 25 g/50 mL (500 mg/mL) ANSYR™ II Plastic Syringe (side/side) | YES | July | October |
| 0409-4902-34 | 50% Dextrose Injection, USP 25 g/50 mL (500 mg/mL) LifeShield™ ABBOJECT™ Glass Syringe (18 G x 1 1/2") | YES | June | Late August |
| 0409-4921-34 | Epinephrine Injection, USP 1 mg/10 mL (0.1 mg/mL) LifeShield™ ABBOJECT™ Glass Syringe (20 G x 1 1/2") | YES | Early July | September |
| 0409-5534-34 | Sodium Bicarbonate Injection, USP (Infant) 5 mEq/10 mL (0.5 mEq/mL) LifeShield™ ABBOJECT™ Glass Syringe with Male Luer Lock Adapter and 20-Gauge protected needle (4.2% concentration) | YES | Late June | January - March 2018 |

| | | | | |
|--------------|--|-----|--------------|----------------------|
| 0409-4916-34 | Sodium Bicarbonate Injection, USP 44.6 mEq/50 mL (0.9 mEq/mL) LifeShield™ ABBOJECT™ Glass Syringe with Male Luer Lock Adapter and 18-Gauge protected needle (7.5% concentration) | YES | October | January - March 2018 |
| 0409-6637-34 | Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL) LifeShield™ ABBOJECT™ Glass Syringe (18 G x 1 1/2") (8.4% concentration) | YES | Late June | January - March 2018 |
| 0409-4900-34 | Sodium Bicarbonate Injection, USP (Pediatric) 10 mEq/10 mL (1 mEq/mL) LifeShield™ ABBOJECT™ Glass Syringe with Male Luer Lock Adapter and 20-Gauge protected needle (8.4% concentration) | YES | Early August | January - March 2018 |